Difference between revisions of "Carmustine wafer, polifeprosan 20 (Gliadel wafer)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Biodegradable copolymer matrix (polifeprosan 20) embedded with carmustine, a nitrosourea which alkylates DNA and RNA and inhibits several key enzymatic processes by carbamoylation of amino acids in proteins. Each Gliadel wafer is 1.45 cm in diameter and 1 mm thick and contains 192.3 mg copolymer and 7.7 mg carmustine. Exposure to the surgical resection cavity results in hydrolyzation of anhydride bonds of the copolymer, which releases carmustine.<ref name="insert">[http://www.gliadel.com/Docs/Pdf/201241R1_Gliadel_PI.pdf Carmustine wafer, polifeprosan 20 (Gliadel) package insert]</ref><ref>[[Media:Carmustinewafer.pdf | Carmustine wafer, polifeprosan 20 (Gliadel) package insert (locally hosted backup)]]</ref><ref>[http://www.gliadel.com/ Gliadel manufacturer's website]</ref> | Class/mechanism: Biodegradable copolymer matrix (polifeprosan 20) embedded with carmustine, a nitrosourea which alkylates DNA and RNA and inhibits several key enzymatic processes by carbamoylation of amino acids in proteins. Each Gliadel wafer is 1.45 cm in diameter and 1 mm thick and contains 192.3 mg copolymer and 7.7 mg carmustine. Exposure to the surgical resection cavity results in hydrolyzation of anhydride bonds of the copolymer, which releases carmustine.<ref name="insert">[http://www.gliadel.com/Docs/Pdf/201241R1_Gliadel_PI.pdf Carmustine wafer, polifeprosan 20 (Gliadel) package insert]</ref><ref>[[Media:Carmustinewafer.pdf | Carmustine wafer, polifeprosan 20 (Gliadel) package insert (locally hosted backup)]]</ref><ref>[http://www.gliadel.com/ Gliadel manufacturer's website]</ref> | ||
| Line 9: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Glioblastoma]] |
| + | *[[:Category:High-grade gliomas|High-grade glioma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 17: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 9/23/1996: Inital FDA approval | * 9/23/1996: Inital FDA approval | ||
| + | * Current indications: | ||
| + | ** Newly diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation | ||
| + | ** Recurrent [[glioblastoma|glioblastoma multiforme]] patients as an adjunct to surgery | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Generic name:''' polifeprosan 20 with carmustine implant | ||
| + | *'''Brand name:''' Gliadel wafer | ||
==References== | ==References== | ||
| Line 22: | Line 28: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | [[Category: | + | [[Category:Intralesional medications]] |
[[Category:Nitrosoureas]] | [[Category:Nitrosoureas]] | ||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
| − | [[Category: | + | [[Category:Glioblastoma medications]] |
| + | [[Category:High-grade glioma medications]] | ||
[[Category:Drugs FDA approved in 1996]] | [[Category:Drugs FDA approved in 1996]] | ||
Revision as of 02:51, 28 January 2018
General information
Class/mechanism: Biodegradable copolymer matrix (polifeprosan 20) embedded with carmustine, a nitrosourea which alkylates DNA and RNA and inhibits several key enzymatic processes by carbamoylation of amino acids in proteins. Each Gliadel wafer is 1.45 cm in diameter and 1 mm thick and contains 192.3 mg copolymer and 7.7 mg carmustine. Exposure to the surgical resection cavity results in hydrolyzation of anhydride bonds of the copolymer, which releases carmustine.[1][2][3]
Route: implanted wafer
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (Chemocare)[4]
- Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 9/23/1996: Inital FDA approval
- Current indications:
- Newly diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation
- Recurrent glioblastoma multiforme patients as an adjunct to surgery
Also known as
- Generic name: polifeprosan 20 with carmustine implant
- Brand name: Gliadel wafer
References
- ↑ 1.0 1.1 Carmustine wafer, polifeprosan 20 (Gliadel) package insert
- ↑ Carmustine wafer, polifeprosan 20 (Gliadel) package insert (locally hosted backup)
- ↑ Gliadel manufacturer's website
- ↑ Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (Chemocare)
- ↑ Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (UpToDate)